AR133027A1 - Composición farmacéutica que comprende un compuesto de quinazolina - Google Patents
Composición farmacéutica que comprende un compuesto de quinazolinaInfo
- Publication number
- AR133027A1 AR133027A1 ARP240101588A ARP240101588A AR133027A1 AR 133027 A1 AR133027 A1 AR 133027A1 AR P240101588 A ARP240101588 A AR P240101588A AR P240101588 A ARP240101588 A AR P240101588A AR 133027 A1 AR133027 A1 AR 133027A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- quinazoline compound
- compound
- salt
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1) o una sal de este, para su uso en el tratamiento del cáncer colorrectal y/o del cáncer de pulmón. Una composición farmacéutica, para tratar el cáncer colorrectal y/o de pulmón, que comprende un compuesto de acuerdo con la fórmula (1), o una sal de este, como se define en cualquiera de las reivindicaciones 1 a 11, y uno o más excipientes aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23180998 | 2023-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133027A1 true AR133027A1 (es) | 2025-08-20 |
Family
ID=86942431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101588A AR133027A1 (es) | 2023-06-22 | 2024-06-19 | Composición farmacéutica que comprende un compuesto de quinazolina |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN121240888A (es) |
| AR (1) | AR133027A1 (es) |
| AU (1) | AU2024313328A1 (es) |
| IL (1) | IL324684A (es) |
| TW (1) | TW202500146A (es) |
| WO (1) | WO2024261257A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322247A (en) | 2023-01-26 | 2025-09-01 | Arvinas Operations Inc | Cerebellon-based KRAS-disrupting proteins and related uses |
| WO2025159142A1 (ja) * | 2024-01-24 | 2025-07-31 | アステラス製薬株式会社 | Ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2025168124A1 (zh) * | 2024-02-08 | 2025-08-14 | 杭州多域生物技术有限公司 | 喹唑啉类化合物、其药物组合物及其应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| KR20220101015A (ko) | 2014-04-14 | 2022-07-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN112218859B (zh) | 2018-04-04 | 2024-10-29 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2020018788A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| PH12022550469A1 (en) | 2019-08-29 | 2023-02-27 | Array Biopharma Inc | Kras g12d inhibitors |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| JP2023531269A (ja) | 2020-06-30 | 2023-07-21 | インベンティスバイオ カンパニー リミテッド | キナゾリン化合物、その製造方法および用途 |
| EP4182313A4 (en) | 2020-07-16 | 2024-10-09 | Mirati Therapeutics, Inc. | KRAS-G12D INHIBITORS |
| US20230339976A1 (en) | 2020-08-04 | 2023-10-26 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US20240034733A1 (en) | 2020-11-03 | 2024-02-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| CR20230404A (es) * | 2021-02-15 | 2023-09-21 | Astellas Pharma Inc | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d |
| CN115260158A (zh) * | 2021-04-30 | 2022-11-01 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| WO2023280026A1 (zh) * | 2021-07-05 | 2023-01-12 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| WO2023077441A1 (en) | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| EP4491624A1 (en) * | 2022-03-11 | 2025-01-15 | Astellas Pharma Inc. | Heterocyclic compound for inducing degradation of g12d mutant kras protein |
-
2024
- 2024-06-19 AR ARP240101588A patent/AR133027A1/es unknown
- 2024-06-21 CN CN202480033826.XA patent/CN121240888A/zh active Pending
- 2024-06-21 WO PCT/EP2024/067467 patent/WO2024261257A1/en active Pending
- 2024-06-21 TW TW113123122A patent/TW202500146A/zh unknown
- 2024-06-21 AU AU2024313328A patent/AU2024313328A1/en active Pending
-
2025
- 2025-11-16 IL IL324684A patent/IL324684A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024313328A1 (en) | 2025-11-20 |
| CN121240888A (zh) | 2025-12-30 |
| IL324684A (en) | 2026-01-01 |
| WO2024261257A1 (en) | 2024-12-26 |
| TW202500146A (zh) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133027A1 (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| GEAP202315648A (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| AR133028A1 (es) | Composición farmacéutica que comprende un degradador de todas las kras | |
| MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| CL2021002217A1 (es) | Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda | |
| CL2024003232A1 (es) | Compuestos derivados de heteroarilo y uso para tratar el dolor. | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| MX2019009266A (es) | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer. | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| AR126849A1 (es) | Compuestos de quinazolina para tratamiento de enfermedad | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. |